TNFRSF8 and lymphoma: The combination of BV with the first-generation ABCB1 inhibitor verapamil is presently being explored in CD30-positive lymphoma (clinical trial NCT03013933).42 However, this is the first preclinical study of the third-generation inhibitor tariquidar in eIMS.